Äbelö Angela, Smallridge John W, von Rotz Robin, Dornbierer Dario A, Egger Klemens, Ashton Michael, Scheidegger Milan
Department of Pharmacology, University of Gothenburg, Sweden.
Reconnect Labs AG, Winterthur, Switzerland.
Biomed Pharmacother. 2025 Aug;189:118329. doi: 10.1016/j.biopha.2025.118329. Epub 2025 Jul 9.
N,N-dimethyltryptamine (DMT) is a psychedelic compound commonly co-administered with the monoamine oxidase inhibitor harmine in ayahuasca-inspired formulations. However, the impact of harmine on DMT pharmacokinetics (PK) and pharmacodynamics (PD) remains insufficiently characterized. In this single-blind, randomized, two-arm, factorial, dose-finding study, 16 healthy participants (9 males, 7 females) received six combinations of buccal DMT (0-120 mg) and harmine (0-180 mg) via a microcarrier-based transmucosal delivery system. Plasma concentrations and subjective intensity ratings of psychedelic effects were collected and analyzed using nonlinear mixed-effects modeling in NONMEM. A one-compartment model with delayed absorption, incorporating three transit compartments, best described the PK of DMT. Allometric scaling based on body weight improved the model fit, revealing significant interindividual variability in clearance and bioavailability. Harmine markedly enhanced DMT bioavailability and prolonged its absorption, resulting in higher and more sustained plasma concentrations. The relationship between DMT plasma concentrations and subjective drug effect intensity was captured by a sigmoidal maximum effect model, which demonstrated considerable variability in individual sensitivity to psychedelic effects. Model-based simulations showed a clear dose-dependent increase in subjective intensity for both DMT and harmine, with a potentiating effect observed at higher DMT doses when combined with escalating harmine doses. These findings provide a comprehensive population PK/PD framework that elucidates how harmine influences DMT exposure and subjective effects. By quantifying key sources of variability, this work provides a proof-of-concept approach applied to a specific population and dosing regimen, which lays the foundation for more precise, personalized dosing strategies in psychedelic-assisted therapy.
N,N-二甲基色胺(DMT)是一种迷幻化合物,在受死藤水启发的配方中通常与单胺氧化酶抑制剂 harmine 共同使用。然而,harmine 对 DMT 药代动力学(PK)和药效学(PD)的影响仍未得到充分表征。在这项单盲、随机、双臂、析因、剂量探索研究中,16 名健康参与者(9 名男性,7 名女性)通过基于微载体的透粘膜给药系统接受了六种颊部 DMT(0 - 120 mg)和 harmine(0 - 180 mg)的组合。使用 NONMEM 中的非线性混合效应模型收集并分析了血浆浓度和迷幻效果的主观强度评分。一个包含三个转运室的具有延迟吸收的单室模型最能描述 DMT 的 PK。基于体重的异速生长标度改善了模型拟合,揭示了清除率和生物利用度存在显著的个体间变异性。Harmine 显著提高了 DMT 的生物利用度并延长了其吸收时间,导致血浆浓度更高且更持久。DMT 血浆浓度与主观药物效应强度之间的关系由一个 S 型最大效应模型描述,该模型表明个体对迷幻效果的敏感性存在相当大的变异性。基于模型的模拟显示,DMT 和 harmine 的主观强度均有明显的剂量依赖性增加,当较高剂量的 DMT 与递增剂量的 harmine 联合使用时,观察到增强效应。这些发现提供了一个全面的群体 PK/PD 框架,阐明了 harmine 如何影响 DMT 的暴露和主观效应。通过量化变异性的关键来源,这项工作为应用于特定人群和给药方案的概念验证方法提供了依据,为迷幻辅助治疗中更精确、个性化的给药策略奠定了基础。